The U.S. Food and Drug Administration has amended the emergency use authorization [EUA] for the Pfizer-BioNTech Covid-19 vaccine to “expand the use of a single booster dose to include use in individuals 12 through 15 years of age, shorten the time between the completion of primary vaccination of the Pfizer-BioNTech Covid-19 Vaccine and a booster dose to at least five months and allow for a third primary series dose for certain immunocompromised children 5 through 11 years of age.”
“Throughout the pandemic, as the virus that causes Covid-19 has continuously evolved, the need for the FDA to quickly adapt has meant using the best available science to make informed decisions with the health and safety of the American public in mind,” said Acting FDA Commissioner Janet Woodcock, M.D.
“With the current wave of the omicron variant, it’s critical that we continue to take effective, life-saving preventative measures such as primary vaccination and boosters, mask wearing and social distancing to in order to effectively fight Covid-19.”
